Literature DB >> 19029642

The combinations C1 esterase inhibitor with coagulation factor XIII and N-acetylcysteine with tirilazad mesylate reduce the leukocyte adherence in an experimental endotoxemia in rats.

Jürgen Birnbaum1, Edda Klotz, Claudia D Spies, Ortrud Vargas Hein, Katja Mallin, Renata Kawka, Sabine Ziemer, Christian Lehmann.   

Abstract

The study's objective was to determine the effects of the administration of combinations of C1 esterase inhibitor (C1-INH) with coagulation factor XIII (F XIII) and N-acetylcysteine (NAC) with tirilazad mesylate (TM) on leukocyte adherence and on intestinal functional capillary density during experimental endotoxemia in rats. In a prospective, randomized, controlled animal study, 40 male Wistar rats were divided into 4 groups. Group 1 (CON group) served as control group. Group 2 (LPS group), group 3 (C1-INH+F XIII group) and group 4 (NAC+TM group) received endotoxin infusions (10 mg/kg/h for 2 h). In C1-INH+F XIII group, 100 U/kg b.w. C1-INH and 50 U/kg b.w. F XIII were administered after the first 30 min of endotoxemia. In the NAC+TM group, 150 mg/kg b.w. N-acetylcysteine and 10 mg/kg b.w. Tirilazad mesylate were administered after 30 min of endotoxemia. Leukocyte adherence at venules of the intestinal submucosal layer and functional capillary density in the villi intestinales and in the longitudinal and circular muscle layers were estimated by intravital fluorescence microscopy (IVM). C1-INH+F XIII reduced the count of firmly adherent leukocytes that was increased after LPS administration in the V3 venules (CON group 69 (17-160)/mm2; LPS group 635 (556-814)/mm2; C1-INH+F XIII group 503 (337-646)/mm2). NAC+TM reduced the firmly adherent leukocytes in the V3 venules (NAC+TM group 403 (309-572)/mm2) and in the V1 venules (CON group 55 (16-131)/mm2; LPS group 368 (306-475)/mm2; NAC+TM group 270 (216-308)/mm2) as well. FCD was not impaired after LPS challenge and there was no influence of both combinations on the FCD. We conclude that both drug combinations can reduce the leukocyte adherence in a sepsis model in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029642

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  3 in total

1.  Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.

Authors:  Masatake Matsuoka; Tokifumi Majima; Tomohiro Onodera; Masahiro Ieko; Masayoshi Souri; Akitada Ichinose; Takashi Kurita; Yasuhiko Kasahara; Masahiro Inoue; Daisuke Takahashi
Journal:  Int J Hematol       Date:  2012-10-16       Impact factor: 2.490

2.  C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.

Authors:  A Landsem; E W Nielsen; H Fure; D Christiansen; J K Ludviksen; J D Lambris; B Østerud; T E Mollnes; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

3.  Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors.

Authors:  Pedro Mejia; Monica Diez-Silva; Faustin Kamena; Fengxin Lu; Stacey M Fernandes; Peter H Seeberger; Alvin E Davis; James R Mitchell
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.